| Abstract: | This pape criticizes the concept of 'technological discontinuities'. It argues that the concept is misleading when the skills and knowledge of an indusry are composed of multiple rather than single core technologies. In cases such as the use of genetic engineering as the basis of production in pharmaceuticals, both existing pharmaceutical firms and new biotech firms integrate the new techniques into existing indusrial practice. The radical tecnology both enhances and destroys existing knowledge; the key to survival has been integration. Both existing and new firms have had the possibility of integrating multiple core technologies, but firms have been able to do so in different ways. Some existing firms could jump over to the radically new 'technological trajectory', by combining their creation of new competencies through in-house R&D with their access to novelty through relations with external agents in systems of innovation. |
